HEMOGENYX Financial Statements From 2010 to 2024
| 5HU Stock | EUR 4.14 0.62 13.03% |
Check HEMOGENYX PHARMPLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HEMOGENYX PHARMPLC's main balance sheet or income statement drivers, such as , as well as many indicators such as . HEMOGENYX financial statements analysis is a perfect complement when working with HEMOGENYX PHARMPLC Valuation or Volatility modules.
HEMOGENYX |
HEMOGENYX PHARMPLC LS 01 Company EBITDA Analysis
HEMOGENYX PHARMPLC's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current HEMOGENYX PHARMPLC EBITDA | (2.62 M) |
Most of HEMOGENYX PHARMPLC's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HEMOGENYX PHARMPLC LS 01 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, HEMOGENYX PHARMPLC LS 01 reported earnings before interest,tax, depreciation and amortization of (2.62 Million). This is 100.3% lower than that of the Healthcare sector and 102.62% lower than that of the Biotechnology industry. The ebitda for all Germany stocks is 100.07% higher than that of the company.
HEMOGENYX PHARMPLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HEMOGENYX PHARMPLC's current stock value. Our valuation model uses many indicators to compare HEMOGENYX PHARMPLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HEMOGENYX PHARMPLC competition to find correlations between indicators driving HEMOGENYX PHARMPLC's intrinsic value. More Info.HEMOGENYX PHARMPLC LS 01 is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HEMOGENYX PHARMPLC's earnings, one of the primary drivers of an investment's value.About HEMOGENYX PHARMPLC Financial Statements
HEMOGENYX PHARMPLC stakeholders use historical fundamental indicators, such as HEMOGENYX PHARMPLC's revenue or net income, to determine how well the company is positioned to perform in the future. Although HEMOGENYX PHARMPLC investors may analyze each financial statement separately, they are all interrelated. For example, changes in HEMOGENYX PHARMPLC's assets and liabilities are reflected in the revenues and expenses on HEMOGENYX PHARMPLC's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in HEMOGENYX PHARMPLC LS 01. Please read more on our technical analysis and fundamental analysis pages.
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company was incorporated in 2013 and is headquartered in London, the United Kingdom. HEMOGENYX PHARM is traded on Frankfurt Stock Exchange in Germany.
Currently Active Assets on Macroaxis
Other Information on Investing in HEMOGENYX Stock
HEMOGENYX PHARMPLC financial ratios help investors to determine whether HEMOGENYX Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HEMOGENYX with respect to the benefits of owning HEMOGENYX PHARMPLC security.